

Research use only. Not for use in diagnostic procedures

$N-\alpha$ -NICOTINOYL-[125 I]Tyr-($N-\alpha$ -CBZ-Arg)-Lys-His-Pro-IIe-OH

Product Number: NEX324

[125] II-CGP 42112A

LOT SPECIFIC INFORMATION

CALCULATED AS OF: 18-Dec-2023

LOT NUMBER: HG22340

SPECIFIC ACTIVITY: 81.4 TBq/mmol

> 2200 Ci/mmol 69.2 MBq/µg 1871 μCi/μg

RADIOCHEMICAL PURITY: >95%

MOLECULAR WEIGHT: 1176

Package Size Information								
Package Size								

Package Size
as of
23-Feb-2024
185 kBq
5 μCi
925 kBq
25 μCi

PACKAGING: [125]-CGP 42112A is lyophilized from a solution containing 0.05M sodium phosphate, 0.18M sodium chloride, 1M glycine, 0.25% BSA, at pH 5.2. It is shipped ambient.

STABILITY AND STORAGE: The lyophilized [1251]-CGP 42112A should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 25 µCi/ml on calibration date, aliquot and store at -20°C. Under these conditions the product is stable and usable for nine to ten weeks after fresh lot date.

SPECIFIC ACTIVITY: The initial specific activity of [125]-CGP 42112A is 2200 Ci/mmol (81 TBq/mmol), 1871 µCi/µg (69 MBq/μg). Preparative HPLC is used to separate CGP 42112A from [125I]-CGP 42112A. Upon decay, [125I]-CGP 42112A undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular or peptide fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on 125I decay and decay catastrophe of 125I labeled compounds are available.1-5

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC.

PREPARATIVE PROCEDURE: CGP 42112A is radioiodinated with no carrier added ¹²⁵I using a modification of the Hunter and Greenwood method⁶ and purified by reversed phase HPLC.

AVAILABILITY: [1251]-CGP 42112A is routinely available from stock and is prepared fresh and packaged for shipment on the third Monday of February, April, June, August, October and December. Please inquire for larger package sizes.

APPLICATIONS: Extremely high selectivity makes ¹²⁵I-CGP 42112A very useful for competitive binding assays, isolation of receptors, and autoradiography.7-11 Binding studies succeed even with difficult tissues, tissues with low AT₂ densities or mixtures of angiotensin receptor subtypes.¹⁰ 125 I-CGP 42112A helps in purifying and characterizing AT₂ receptors from immature rat kidney.¹¹ 125 I-CGP 42112A is the best choice for autoradiographic studies of AT₂ receptors.⁸ The properties of high selectivity, affinity, stability, and specific activity make NEX324 an attractive tool for studies of the angiotensin AT₂ receptor.

HAZARD WARNING: This product contains a chemical(s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, skin and respiratory tract. It is toxic.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., Eur. J. Pharm. 99 353 (1984).
- 2. Schmidt, J., J. Biol. Chem. 259 1160 (1984).
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Rad. Res. 82 467 (1980).
- Charlton, D.E., Rad. Res. 107 163 (1986).
- 6. Hunter, W.M. and Greenwood, F.C., Nature 194 495 (1962).
- 7. Balla, T. Baukal, A.J., Eng, S., Catt, K.J. Mol. Pharmacology 40 401-6 (1991).
- 8. Heemskerk, F.M.J., Zorad, S., Seltzer, A., Saavedra, J.M., NeuroReport 4(1) 103-5 (1993).
- 9. Sumners, C., Tang, W., Zelezna, B., Raizada, M.K., *Proc. Natl Acad. Sci.* USA <u>88</u> 7567-71 (1991).
- 10. Whitebread, S.E., Taylor, V., Bottari, S.P., Kamber, B., de Gasparo, M., Biochem. Biophys. Res. Comm. 181(3)
- 11. Ciuffo, G.M., Heemskerk, F.M.J., Saavedra, J.M., Proc. Natl Acad. Sci. USA 90 11009-13 (1993).

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831	0.812
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.66	0.645
40	0.63	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524	0.512
60	0.5	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416	0.406
80	0.397	0.388	0.379	0.37	0.362	0.354	0.345	0.338	0.33	0.322
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262	0.256
120	0.25	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208	0.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com

For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.